473 related articles for article (PubMed ID: 34502225)
1. Extracellular Heat Shock Proteins as Therapeutic Targets and Biomarkers in Fibrosing Interstitial Lung Diseases.
Tanguy J; Pommerolle L; Garrido C; Kolb M; Bonniaud P; Goirand F; Bellaye PS
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502225
[TBL] [Abstract][Full Text] [Related]
2. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
3. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
Makino S
Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
[TBL] [Abstract][Full Text] [Related]
4. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
Wollin L; Distler JHW; Redente EF; Riches DWH; Stowasser S; Schlenker-Herceg R; Maher TM; Kolb M
Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31285305
[TBL] [Abstract][Full Text] [Related]
5. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Sarr C; Freiwald M
BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823
[TBL] [Abstract][Full Text] [Related]
6. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Magnusson MO; Freiwald M
Respir Med; 2021; 180():106369. PubMed ID: 33798871
[TBL] [Abstract][Full Text] [Related]
7. Endotype-phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease.
Hoffmann-Vold AM; Weigt SS; Saggar R; Palchevskiy V; Volkmann ER; Liang LL; Ross D; Ardehali A; Lynch JP; Belperio JA
EBioMedicine; 2019 Dec; 50():379-386. PubMed ID: 31732480
[TBL] [Abstract][Full Text] [Related]
8. Pathological Insight into 5-HT
Löfdahl A; Tornling G; Wigén J; Larsson-Callerfelt AK; Wenglén C; Westergren-Thorsson G
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33379351
[TBL] [Abstract][Full Text] [Related]
9. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs).
Spagnolo P; Distler O; Ryerson CJ; Tzouvelekis A; Lee JS; Bonella F; Bouros D; Hoffmann-Vold AM; Crestani B; Matteson EL
Ann Rheum Dis; 2021 Feb; 80(2):143-150. PubMed ID: 33037004
[TBL] [Abstract][Full Text] [Related]
11. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management.
Wijsenbeek M; Kreuter M; Olson A; Fischer A; Bendstrup E; Wells CD; Denton CP; Mounir B; Zouad-Lejour L; Quaresma M; Cottin V
Curr Med Res Opin; 2019 Nov; 35(11):2015-2024. PubMed ID: 31328965
[No Abstract] [Full Text] [Related]
12. Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis.
Olson AL; Patnaik P; Hartmann N; Bohn RL; Garry EM; Wallace L
Adv Ther; 2021 Jul; 38(7):4100-4114. PubMed ID: 34156606
[TBL] [Abstract][Full Text] [Related]
13. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?
de Lauretis A; Veeraraghavan S; Renzoni E
Chron Respir Dis; 2011; 8(1):53-82. PubMed ID: 21339375
[TBL] [Abstract][Full Text] [Related]
14. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
Singer D; Bengtson LGS; Conoscenti CS; Laouri M; Shetty SS; Anderson AJ; Brown KK
Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
[No Abstract] [Full Text] [Related]
15. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary fibrosis associated with rheumatoid arthritis: from pathophysiology to treatment strategies.
Diesler R; Cottin V
Expert Rev Respir Med; 2022 May; 16(5):541-553. PubMed ID: 35695895
[TBL] [Abstract][Full Text] [Related]
17. The natural history of progressive fibrosing interstitial lung diseases.
Kolb M; Vašáková M
Respir Res; 2019 Mar; 20(1):57. PubMed ID: 30871560
[TBL] [Abstract][Full Text] [Related]
18. Serum and bronchoalveolar lavage fluid levels of soluble B7H3 in patients with interstitial lung diseases.
Nakashima T; Omori K; Namba M; Yamaguchi K; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Iwamoto H; Fujitaka K; Hamada H; Hattori N
Respir Med; 2023 Jun; 212():107224. PubMed ID: 37003499
[TBL] [Abstract][Full Text] [Related]
19. Association between Pepsin in Bronchoalveolar Lavage Fluid and Prognosis of Chronic Fibrosing Interstitial Lung Disease.
Kim Y; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
Tohoku J Exp Med; 2018 Nov; 246(3):147-153. PubMed ID: 30405002
[TBL] [Abstract][Full Text] [Related]
20. Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype.
Nili M; Singer D; Hanna M
BMC Pulm Med; 2022 Apr; 22(1):153. PubMed ID: 35459138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
